Partnerships
Developing transformational therapies together
We have significant collaborative drug discovery programmes with Takeda Pharmaceuticals in advanced liver fibrosis and NASH in MASH and IBD and with Dompé farmaceutici to enable identification and engineering of new precision medicines against fibro-inflammatory diseases.
Engitix’s portfolio strategy is focused on targeting novel, disease-related mechanisms identified using our ECM-based discovery platform.
Our portfolio programmes span novel antifibrotic treatments that target fibrogenesis across a range of indications, and tumour stroma-targeted therapies to eliminate solid tumours.
Current
collaborations
Takeda Pharmaceuticals
Collaboration and Licensing agreement to develop new anti-fibrotic therapies in inflammatory bowel disease (IBD)
This collaboration builds on our existing collaboration in advanced liver diseases and combines Engitix’s unique human extracellular matrix (ECM) platform with Takeda’s world-leading expertise in gastroenterology research and development (R&D) and commercialisation.
“Partnerships are central to our R&D strategy, forming collaborations anchored around novel scientific approaches in disease areas where patients’ needs are greatest. Engitix’s ECM platform will help accelerate the identification and validation of novel targets that will be valuable in our search for better therapies for all those affected by GI and liver diseases.”
Dr Gareth Hicks, Head of the GI Drug Discovery Unit at Takeda
Dompé farmaceutici
Collaboration and Investment agreement to accelerate the clinical translation of fibrosis and solid tumours targets and discovery of precision engineered medicines
The collaboration combines the power of Exscalate, Dompé’s AI supercomputer structure-based drug design platform, and it’s drug discovery expertise with Engitix’s patient-centric ECM platform and deep understanding of the human ECM.
“Our mission is to improve people’s lives and we partner with the best groups to accelerate research that will bring new solutions to patients. Working together enables us to combine the power of Exscalate with Engitix’s deep understanding of the biology of fibrosis and solid tumours and the unique strength of its ECM platform. Our collaboration will enable us to accelerate the clinical translation of targets beyond our four key in-house therapeutic areas.”
Marcello Allegretti, CSO of Dompé farmaceutici
Takeda Pharmaceuticals
Licensing and Collaboration agreement to discover and develop novel therapeutics for advanced fibrotic liver diseases.
This collaboration combines the strengths of Engitix’s unique ECM platform with Takeda’s world-leading expertise in gastroenterology research and development and commercialisation.
“There is a vital need for new treatments that will positively impact the lives of patients with advanced liver diseases. Engitix’s ECM platform offers a powerful tool for identifying and validating novel targets that will be valuable in the development of direct anti-fibrotic therapies. Our partnership with Engitix underscores our commitment to explore innovative approaches to treat late-stage liver disease.”
Dr Gareth Hicks, Head of the GI Drug Discovery Unit at Takeda
Previous Partnerships
Between 2019 and 2021, we had a Research and Collaboration agreement with Morphic Therapeutics, where we successfully established a disease-specific human fibrostenotic ECM platform for target ID in IBD and Crohn’s disease.
Let's reshape the future of therapeutic discovery together
We are interested in forming collaborations with pharma and biotech companies to unleash the full discovery potential of our platform and expand into additional therapeutic areas.
